Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Share-based Compensation: 2009-2025

Historic Share-based Compensation for BIO-TECHNE (TECH) over the last 17 years, with Jun 2025 value amounting to $40.8 million.

  • BIO-TECHNE's Share-based Compensation rose 14.71% to $11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.3 million, marking a year-over-year increase of 11.01%. This contributed to the annual value of $40.8 million for FY2025, which is 7.34% up from last year.
  • As of FY2025, BIO-TECHNE's Share-based Compensation stood at $40.8 million, which was up 7.34% from $38.0 million recorded in FY2024.
  • Over the past 5 years, BIO-TECHNE's Share-based Compensation peaked at $51.8 million during FY2021, and registered a low of $38.0 million during FY2024.
  • In the last 3 years, BIO-TECHNE's Share-based Compensation had a median value of $39.2 million in 2023 and averaged $39.4 million.
  • In the last 5 years, BIO-TECHNE's Share-based Compensation spiked by 51.32% in 2021 and then dropped by 15.45% in 2023.
  • Over the past 5 years, BIO-TECHNE's Share-based Compensation (Yearly) stood at $51.8 million in 2021, then dropped by 10.50% to $46.4 million in 2022, then declined by 15.45% to $39.2 million in 2023, then fell by 3.03% to $38.0 million in 2024, then grew by 7.34% to $40.8 million in 2025.